加载中
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
前收盘价
US$8.87
+US$0.12 · +1.37%
盘中时间采用ET。市场数据可能有所延迟。
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
日内区间
当前US$8.87
52周区间
当前US$8.87
盘中时间采用ET。市场数据可能有所延迟。
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
日内区间
当前US$8.87
52周区间
当前US$8.87
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.00
上涨空间 136.75%报告持有此股票敞口的交易所交易基金。
Simplify Health Care ETFPINK968.65万3.04%3.19亿 USD0.51%US$38.527+2.57%
Vanguard Morningstar Total Stock Market ETFVTI790.49万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM477.09万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF353.46万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO148.89万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC58.46万0.04%13.17亿 USD0.60%US$183+0.11%
Global X - Genomics & Biotechnology ETFGNOM22.78万0.21%1.04亿 USD0.50%US$68.75+4.44%
Vanguard Russell 2000 Value ETFVTWV22.64万0.02%14亿 USD0.06%US$185.81-0.13%Simplify Health Care ETFPINKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGlobal X - Genomics & Biotechnology ETFGNOMVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
